MDS

1:12
Hypomethylating agents for low risk MDS
Eunice Wang
1:32
IDH inhibitors for AML and MDS
Eunice Wang
3:41
Computational methods are the future of biological research
Dominique Bonnet
3:38
A new set of treatment options for low-risk MDS
Esther Oliva
1:44
A worldwide Phase III trial treating AML with pracinostat
Guillermo Garcia-Manero
3:36
Highlights: ASCO 2018 oral abstract presentations
Guillermo Garcia-Manero
0:47
Targeting DNA methylation as a therapeutic target in multiple myeloma
Benjamin Barwick
0:52
Therapeutics targeting splicing in hematological malignancies
Omar Abdel-Wahab
3:55
The molecular mechanisms of epigenetic therapies: LTRs and TINATs
Christoph Plass
1:43
The drugs being used to treat newly diagnosed AML patients
Mark Levis
1:41
The future of AML and MDS diagnosis and treatment
Stéphane de Botton
1:02
Bispecific agents: the future of AML and MDS treatment?
John DiPersio
0:52
HARMONY: a collaboration between 51 partners
Lars Bullinger
5:47
Using computational algorithms to predict the response of MDS patients to hypomethylating agents
Aziz Nazha
2:39
Film-coated tablet deferasirox formulation for thalassemia and myelodysplastic syndromes (MDS)
Ali T. Taher
3:16
Recognizing clonal hematopoiesis – diagnostic challenges and clinical relevance
Rafael Bejar
The content of VJHemOnc is intended for healthcare professionals